Heptanoic acid pentylamide | 64891-12-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Heptanoic acid pentylamide
• 英文别名: Heptanamide, N-pentyl-；N-pentylheptanamide
• CAS: 64891-12-9
• 化学式: C₁₂H₂₅NO
• mdl: MFCD01753207
• 分子量: 199.337
• InChiKey: GUDYPJBECYDZAH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  14
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.916
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• NOVEL MULTIMERIC CD40 LIGANDS, METHOD FOR PREPARING SAME AND USE THEREOF FOR PREPARING DRUGS
  申请人：Guichard Gilles

  公开号：US20100183642A1

  公开（公告）日：2010-07-22

  The invention concerns a compound of formula (I), wherein Y represents a macrocycle whereof the cycle comprises 9 to 36 atoms, and is functionalized by three amine or COOH functions; R c represents a group of formula H—X a —X b —X c —X d —X e —(X f ) i —, wherein i represents 0 or 1, X n is in particular selected among lysine, arginine, ornithine residues, X b is in particular selected among glycine, asparagine, L-proline or D-proline residues, X c et X d are in particular selected among tyrosine, phenylalanine or 3-nitrotyrosine residues, X e et X f are in particular selected among the following amino acid residues: NH 2 —(CH 2 ) n —COOH, n ranging from 1 to 10 or NH 2 —(CH 2 —CH 2 —O) m —CH 2 CH 2 COOH, m ranging from 3 to 6, provided that one at least of the amino acid residues X a , X b , X c and X d is different from the corresponding amino acid in the sequence of the natural CD40 143 Lys-Gly-Tyr-Tyr 146 fragment

  该发明涉及一种化合物，其化学式为（I），其中Y代表一个大环，该环包含9至36个原子，并且通过三个胺基或COOH功能官能化；Rc代表一个化学式为H—Xa—Xb—Xc—Xd—Xe—（Xf）i—的基团，其中i代表0或1，Xn特别选自赖氨酸、精氨酸、鸟氨酸残基之一，Xb特别选自甘氨酸、天冬氨酸、L-脯氨酸或D-脯氨酸残基之一，Xc和Xd特别选自酪氨酸、苯丙氨酸或3-硝基酪氨酸残基之一，Xe和Xf特别选自以下氨基酸残基之一：NH2—（CH2）n—COOH，其中n取1至10之间的值，或NH2—（CH2—CH2—O）m—CH2CH2COOH，其中m取3至6之间的值，前提是氨基酸残基Xa、Xb、Xc和Xd中至少有一个与天然CD40143Lys-Gly-Tyr-Tyr146片段中相应的氨基酸不同。
• [EN] ANTIBODY DRUG CONJUGATES (ADCS) WITH NAMPT INHIBITORS<br/>[FR] CONJUGUÉS ANTICORPS-MÉDICAMENT (ADC) AVEC DES INHIBITEURS DE NAMPT
  申请人：BAYER PHARMA AG

  公开号：WO2021013693A1

  公开（公告）日：2021-01-28

  Conjugate of a binder having formula (AA) wherein AB stands for a binder, Z' stands for a linker, D stands for an active component which is a NAMPT inhibitor and its use as pharmaceuticals.

  一个具有化学式（AA）的粘合剂的共轭物，其中AB代表粘合剂，Z'代表连接剂，D代表一种活性成分，即NAMPT抑制剂，并且其用作药物。
• PLATINUM COMPOUND OF MALONIC ACID DERIVATIVE HAVING LEAVING GROUP CONTAINING AMINO OR ALKYLAMINO
  申请人：BEIJING FSWELCOME TECHNOLOGY DEVELOPMENT, CO., LTD

  公开号：EP2924044A1

  公开（公告）日：2015-09-30

  Disclosed are a class of platinum compounds of malonic acid derivatives having a leaving group containing an amino or alkylamino, and pharmaceutically acceptable salt thereof, preparation method thereof and pharmaceutical composition containing the compounds. Also disclosed are uses of the compounds for treating cell proliferative diseases especially cancers. The platinum compounds of the present invention have high solubility in water, low toxicity and strong anti-tumor effect.

  本发明公开了一类具有含氨基或烷基氨基离去基团的丙二酸衍生物的铂化合物及其药学上可接受的盐、制备方法和含有该化合物的药物组合物。本发明还公开了这些化合物用于治疗细胞增殖性疾病，特别是癌症的用途。本发明的铂化合物在水中的溶解度高，毒性低，抗肿瘤作用强。
• Aryl dihydropyridinones and piperidinone MGAT2 inhibitors
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US10369140B2

  公开（公告）日：2019-08-06

  The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.

  本发明提供了式 (I) 的化合物： 或其立体异构体，或其药学上可接受的盐，其中所有变量如本文所定义。这些化合物是单酰基甘油酰基转移酶 2 型（MGAT2）抑制剂，可用作药物。
• Platinum Compounds Of Malonic Acid Derivative Having Leaving Group Containing Amino Or Alkylamino
  申请人：BEIJING FSWELCOME TECHNOLOGY DEVELOPMENT CO., LTD

  公开号：US20150368281A1

  公开（公告）日：2015-12-24

  Disclosed are a class of platinum compounds of malonic acid derivatives having a leaving group containing an amino or alkylamino, and pharmaceutically acceptable salt thereof, preparation method thereof and pharmaceutical composition containing the compounds. Also disclosed are uses of the compounds for treating cell proliferative diseases especially cancers. The platinum compounds of the present invention have high solubility in water, low toxicity and strong anti-tumor effect.